Brought to you by 
Series B brings in $35mm for Metastatix
10 Oct 2007
Executive Summary
Metastatix (small-molecule therapeutics for cancer, HIV, and inflammation) raised $35mm through a Series B round that was led by Frazier Healthcare Ventures. Existing backers HIG Ventures, Aurora Funds, CM Capital, SR One, MedImmune Ventures, Georgia Venture Partners, Centrosome Ventures, and the State of Georgia also participated. A partner from Frazier has joined Metastatix's board.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series B brings in $35mm for Metastatix
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice